MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-16-2023
Athersys ROE Ratio 2011-2026 | ATHX
Annual ROE Ratio Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -531.22 | -251.15 | -191.58 | -56.32 | -137.92 | -137.17 | -83.26 | -105.68 | -155.1 | -72.78 | -188.35 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -56.32 | -531.22 | -173.68 |
Quarterly ROE Ratio Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152.37 | 224.29 | 391.24 | -6952.72 | -7085.35 | -7222.76 | -7582.29 | -414.23 | -352.4 | -369.16 | -269.69 | -251.15 | -222.98 | -202.73 | -185.79 | -191.58 | -175.19 | -146.15 | -88.44 | -56.32 | -86.1 | -94.5 | -137.39 | -137.92 | -145.63 | -168.34 | -203.74 | -137.17 | -55.22 | -34.46 | 22.51 | -85.62 | -135.2 | -124.84 | -116.36 | -105.68 | -123.73 | -129.47 | -162.7 | -155.1 | -121.67 | -110.38 | -98.72 | -72.78 | -115.05 | -130.09 | -155.92 | -188.35 | -32.08 | -44.16 | -53.85 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 391.24 | -7582.29 | -675.31 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.95 | -2.5 % | $ 498 M |  Britain |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 11.7 | 21.57 % | $ 757 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-40.17 | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 212.12 | 1.35 % | $ 5 B |  Danmark |
 |
Aclaris Therapeutics
ACRS
|
-84.9 | $ 2.69 | 1.51 % | $ 208 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-288.19 | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 4.72 | 18.59 % | $ 10.3 B |  Israel |
 |
BioNTech SE
BNTX
|
1.11 | $ 101.08 | 3.05 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
21.78 | $ 27.36 | -0.96 % | $ 1.33 B | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-43.38 | $ 0.83 | -2.51 % | $ 113 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 10.99 | -0.72 % | $ 723 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-19.35 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.38 | -1.03 % | $ 2.04 M | USA |
 |
Axon Enterprise
AXON
|
16.2 | $ 619.64 | -1.12 % | $ 46.9 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.84 | 4.41 % | $ 17.8 M | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | $ 94.45 | -0.54 % | $ 96.9 B | Britain |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 4.63 | 5.23 % | $ 116 M | France |
 |
Bellicum Pharmaceuticals
BLCM
|
-1239.35 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 9.32 | 0.27 % | $ 1.51 B | Britain |
 |
bluebird bio
BLUE
|
-108.93 | - | - | $ 546 M | USA |
 |
Biogen
BIIB
|
9.76 | $ 184.21 | 0.87 % | $ 26.8 B | USA |
 |
Cellectar Biosciences
CLRB
|
282.15 | $ 3.24 | 0.62 % | $ 39.6 M | USA |
 |
Abeona Therapeutics
ABEO
|
-365.49 | $ 5.19 | 0.58 % | $ 111 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
20.78 | $ 37.18 | 3.91 % | $ 3.84 B | USA |
 |
ADiTx Therapeutics
ADTX
|
-8126.35 | $ 0.86 | -2.54 % | $ 11.3 K | USA |